Zimeta™ (dipyrone injection) is the FIRST and ONLY drug FDA-approved for the control of pyrexia (fever) in horses.
In clinical studies, Zimeta™ demonstrated rapid and effective control of fever in horses.1,2*
Dipyrone, the active ingredient in Zimeta, is a member of the non-steroidal anti-inflammatory drug (NSAID) class and has a centrally acting mechanism of action on the hypothalamus where fever originates and is regulated.**
In a field study, clinical signs associated with adverse events were reported in less than 2% of Zimeta treated horses.2
This is the first-time dipyrone has been FDA-approved for veterinary use in the United States. Dipyrone, also known as metamizole, is approved and widely used in many other countries.
*When administered according to label directions. **Equine clinical relevance has not been determined.
Zimeta should not be used more frequently than every 12 hours. Do not use in horses with a hypersensitivity to dipyrone. See below for additional important safety information.
Sign up to receive future communications about Zimeta.
For more information or to place an order now:
Contact your preferred animal health distributor, your KindredBio Sales Specialist, or call KindredBio Customer Care at 1-888-608-2542.
Zimeta is indicated for the control of pyrexia in horses.
Important Safety Information
Zimeta™ (dipyrone injection) should not be used more frequently than every 12 hours. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals. Not for use in humans, avoid contact with skin and keep out of reach of children. Take care to avoid accidental self-injection and use routine precautions when handling and using loaded syringes. Prior to use, horses should undergo a thorough history and physical examination. Monitor for clinical signs of coagulopathy and use caution in horses at risk for hemorrhage. Concomitant use with other NSAIDs, corticosteroids and nephrotoxic drugs, should be avoided. As a class, NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. The most common adverse reactions observed during clinical trials were Elevated Serum Sorbitol Dehydrogenase (SDH), Hypoalbuminemia and Gastric Ulcers. For product label, including complete safety information, click here.
Morresey PR, White GW, Poole HM, et al. Randomized blinded controlled trial of dipyrone as a treatment for pyrexia in horses. Am J Vet Res. 2019;80(3):294-299.